Pfizer’s Path To Profit: A Look At PFE Stock As Drugmaker Rolls Out $1.5B In Cost Reductions
Pfizer launched a $1.5 billion cost reduction program to enhance operational efficiencies and cut costs amid declining sales. Stock shows bullish momentum.